brings all the resources available to us and all of our offices to deal with issues in a very rapid manner. So you'll hear Nakissa talk about that.
But there are other research programs at the office level, and at some point, I'll make this committee aware of those programs in much more detail, and I think it's an exciting program that we have on computational toxicology. FDA has probably the best database available on drugs in terms of their safety, efficacy, and a number of things, and if you don't utilize this database effectively, then you're not doing the right thing and you're not learning from the database that we have.
So there's a group within our office which has developed excellent predictive models of toxicology using data that is available to us in our submissions, and many of these software products are available commercially now through a collaborative research and development agreement. So these are structured activity-based, bioinformatics-based predictive tools that we have been developing, and we will be expanding some of the scope of this to drug-drug interaction and other areas too. But that will be for a different advisory committee that will